Best Life Insurance Carriers for Treated Hypertension

What Treated Hypertension Actually Means to an Underwriter

Roughly half of adults over 50 in the United States meet the clinical definition of hypertension. A meaningful portion are on medication. When a life insurance applicant checks "yes" next to high blood pressure on the application, the underwriter is not looking at that checkbox in isolation. They are looking at the full picture: current readings on therapy, how many medications are required to maintain control, how long the diagnosis has existed, whether target-organ damage has shown up on labs or imaging, and what other cardiovascular risk factors sit alongside.

This page is educational. It is not medical or insurance advice. Actual carrier placement depends on attending physician statements, paramedical exam labs, and current carrier appetite.

In underwriting language, "treated hypertension" usually means a diagnosis of hypertension currently managed by medication with acceptable on-treatment readings. Untreated hypertension (a diagnosis that has not been addressed) is a different and more serious picture. A history of hypertensive urgency, hypertensive emergency, or stroke moves the case into a different category entirely.

The good news for most treated-HTN applicants: controlled blood pressure on a single medication, without other cardiovascular red flags, is one of the more forgiving impairments in modern life insurance underwriting. It is not the disqualifier many applicants assume it will be.

Why Treated Hypertension Matters Less Than Many Shoppers Assume

When shoppers see "hypertension" on a preferred criteria chart, they often assume it caps them at Standard or Standard Plus. In practice, most of the 18 carriers modeled in the Lumis Life estimator will still consider the top non-tobacco tier for an applicant whose blood pressure sits comfortably under a typical on-treatment ceiling with a single medication and no end-organ complications.

The reason is actuarial. Once hypertension is controlled, the incremental mortality contribution is modest compared to uncontrolled hypertension or a history of cardiovascular events. Carriers have tracked this data across decades of insured lives. They know that a 55-year-old male with BP at 128/82 on 10 mg of lisinopril, clean lipids, healthy weight, and no family history of early cardiac disease presents a very different mortality picture from an applicant whose blood pressure is labile on three agents.

The more important questions for a treated-HTN applicant are usually:

• How many medications? One agent is typically neutral. Two agents moves most carriers to consider Standard Plus rather than Preferred. Three or more agents usually caps the case at Standard.
• What are the on-treatment readings? A systolic reading above 140 or diastolic above 90 while on therapy suggests control is marginal and moves the case down a tier at most carriers.
• How long has the diagnosis existed? Duration alone is rarely a tier-breaker, but a new diagnosis may warrant a short postponement at some carriers while treatment is optimized.
• Any history of hypertensive urgency, stroke, or TIA? This changes the picture materially and is discussed below.
• Any target-organ damage? Left ventricular hypertrophy on echo, microalbuminuria, or retinopathy signal that hypertension has been present long enough or severe enough to cause structural change. These findings move the case to Standard or rated.

What Carriers Actually Measure

The 18 carriers modeled in the Lumis Life estimator each publish their own treated-HTN thresholds in their field underwriting guides. The structure is broadly similar across the industry but the specific cutoffs vary.

Most carriers define on-treatment BP brackets that map to class tiers. A typical structure looks like:

• Top tier (Preferred Plus, Super Preferred, Preferred Best): On-treatment readings under roughly 135/85, single medication, no history of urgency or stroke, no target-organ damage.
• Second tier (Preferred): On-treatment readings under roughly 140/90, up to two medications allowed at some carriers.
• Standard Plus: Two to three medications, slightly elevated on-treatment readings.
• Standard: Three or more medications, or on-treatment readings above 140/90.

What varies is where each carrier draws the line and which combinations of cholesterol, build, and family history they tolerate alongside treated HTN at the top tier.

How the 18 Carriers Vary on Treated Hypertension

The carriers comparison page shows the full picture for a sample profile: a 58-year-old male with treated hypertension (130/85 on 1 medication), BMI 29, father with MI at 62, and total cholesterol 240. On that profile, the spread between the best-fit carrier and the least competitive carrier is 46 points of top-two-tier probability. Treated HTN is present, but it is not the binding constraint for most of the top-ranked carriers. The combination of family history and cholesterol is doing more of the work.

For a cleaner profile (treated HTN on single med, clean lipids, no family history), the spread compresses. Most carriers will land the applicant somewhere between Preferred and Standard Plus. The differentiators become build, aviation, and pilot rules rather than blood pressure itself.

The Top-Fit Carriers for Treated HTN

Based on the sample profile, the following carriers rank highest for an applicant whose treated hypertension is the most significant factor:

John Hancock (78%). Its field guide is explicit that controlled blood pressure on a single medication with typical on-treatment readings rarely blocks the Preferred Non-Smoker tier. Generous build allowances at ages 50 to 70 reinforce the fit for treated-HTN applicants who are not dealing with a secondary build issue. The tradeoff at John Hancock is a stricter substandard ceiling (Table 8, roughly 300 percent of standard), which matters for heavily impaired cases but does not affect a cleanly treated HTN applicant.

Protective (72%). Protective handles the cholesterol interaction more gracefully than many peers, which matters because treated HTN applicants frequently have mildly elevated lipids. Its cholesterol-ratio rules (rather than absolute total-cholesterol floors) give treated-HTN applicants with favorable HDL more room at the top tier.

Lincoln Financial (70%). Lincoln is competitive across the treated-HTN spectrum and particularly generous at older issue ages. For an applicant in their 60s with well-controlled HTN and clean secondary factors, Lincoln frequently matches or beats peers on top-tier placement.

Symetra (68%). Symetra publishes a clean, predictable preferred grid for treated HTN and tends not to surprise producers with soft declines after paramed review. For straightforward treated-HTN cases without complicating factors, Symetra is a reliable placement.

These four carriers are the top-two-tier best-fit group for the sample profile. The full ranking, including where each carrier lands across all eighteen for the same applicant, is on the carriers comparison page.

When Treated Hypertension Actually Blocks Preferred Tiers

The scenarios where treated HTN genuinely caps the top tiers across most carriers:

Two or more medications. A single-agent regimen is tolerated at the top tier by most carriers. Adding a second agent typically signals that the applicant's natural blood pressure runs higher, requiring more therapy to reach target. Most preferred criteria charts require "BP controlled on one medication" for the top tier.

Elevated on-treatment readings. A systolic reading above 140 or diastolic above 90 while on therapy is a yellow flag at every carrier. It suggests control is incomplete even with treatment. Most carriers will move the case to Standard Plus or Standard, and some will request additional ambulatory BP monitoring or a repeat paramed if the readings are close to the threshold.

History of hypertensive urgency. An ER visit or hospital admission for acutely elevated BP (typically over 180/120) even years in the past changes the underwriting picture. Most carriers will consider the case at Standard or mild substandard depending on how recent, how acute, and what follow-up showed.

Left ventricular hypertrophy on echocardiogram. LVH is structural evidence that hypertension has been present long enough or severe enough to change the heart. Underwriters treat this as a marker of longer-duration uncontrolled or poorly controlled HTN. Most carriers will cap the case at Standard and some will apply a mild substandard rating.

Microalbuminuria or reduced eGFR attributable to hypertension. Kidney involvement, even mild, is another target-organ marker. Most carriers will request additional lab review and place the case at Standard at best.

How Stroke or TIA Changes the Picture

A history of stroke or transient ischemic attack, even remote, takes treated HTN out of the "minor factor" category. Carriers will look at:

• Time since event (most carriers require at least two years, many require five)
• Whether full neurologic recovery was documented
• Whether imaging showed vascular territory involvement
• Whether the cause was identified and addressed (atrial fibrillation, carotid stenosis, patent foramen ovale, etc.)

Well-documented lacunar TIA with full recovery five or more years ago, on optimized secondary prevention (antiplatelet, statin, BP control), can often place at Standard or mild substandard at the more flexible carriers. A more recent event or a residual deficit typically moves the case into substandard territory or a postponement.

This is a category where the spread across carriers widens dramatically. A broker who shops three or four carriers for a post-stroke case will commonly see offers that differ by two or three rating tables.

The Cholesterol Interaction

Treated hypertension rarely travels alone. Most applicants with treated HTN also have at least mildly elevated lipids, and the combination is where carrier rules start to diverge meaningfully.

Protective uses cholesterol ratio rules. The total-to-HDL ratio matters more than absolute total cholesterol at Protective. An applicant with total cholesterol of 240 and HDL of 60 (ratio 4.0) is in a different category at Protective than an applicant with total cholesterol of 240 and HDL of 40 (ratio 6.0), even though the total is identical. For treated-HTN applicants with favorable HDL, this is a real advantage.

AGL (American General) applies a senior cholesterol floor. AGL's preferred criteria tighten cholesterol thresholds for older applicants, on the actuarial reasoning that an applicant in their 60s or 70s has already survived the decades when lipids do most of their atherosclerotic damage. For a 70-year-old applicant with treated HTN and moderately elevated cholesterol, this can be meaningfully more favorable than at peer carriers.

Most carriers use absolute total and LDL thresholds. If total cholesterol sits above roughly 260 or LDL above roughly 180, the top tier is typically out of reach regardless of treatment status, unless the applicant is on a statin with documented reduction from a higher baseline.

The practical takeaway: when treated HTN and elevated cholesterol appear together, the ranking across the 18 carriers can shift by 15 to 25 points of top-tier probability depending on whose ratio rules, age-graded floors, or statin-credit rules happen to be most favorable for the specific applicant.

Practical Advice for Applicants with Treated Hypertension

Bring recent readings to the application. Most carriers request the most recent 12 months of primary-care BP readings via attending physician statement (APS). If the applicant has home-monitored readings (morning and evening averages over 7 to 14 days), those are often useful to share with the underwriter, especially when white-coat elevation is suspected.

Know the medication list cold. The underwriter will see it from the APS and the paramed anyway. Being prepared to discuss current dosage, tolerance, and any changes in the last 12 months makes the conversation faster and reduces the risk of a misclassification based on outdated records.

Stabilize before applying. If the applicant is mid-titration (recently changed doses, recently added a second agent), many brokers recommend waiting 60 to 90 days for on-treatment readings to settle. A paramed taken while the regimen is in flux can produce readings that do not represent the applicant's actual controlled state.

Understand the family-history interaction. An applicant with treated HTN and a parent who died of an MI at 55 is underwritten differently from an applicant with treated HTN and parents who lived to 90. The family history is usually the lever that matters more than the treated HTN itself at the top tier. See family history of early heart disease for how carriers vary on that factor.

Get a broker to shop at least three carriers. Given the spread across the 18 carriers in the estimator, committing to a single carrier without shopping is leaving money on the table. A broker with appointments at the top-fit carriers for the specific profile (the carriers page shows where each applicant ranks) can often improve placement by one full class tier.

What About Older Applicants?

Hypertension is more common in older applicants, and carriers know this. Most field guides apply slightly more generous BP thresholds at older issue ages, reflecting the reality that a 70-year-old with no HTN is the exception rather than the rule.

The tradeoff at older ages is that other factors (build, cholesterol, family longevity) start doing more of the underwriting work. An applicant in their 70s with treated HTN, clean lipids, good build, and long-lived parents is frequently a top-tier candidate at the more generous carriers. The same applicant with any two of those factors out of range is more likely to land at Standard Plus or Standard.

Carriers that handle older applicants with treated HTN particularly well include those with explicit senior-age preferred tiers and those with family-longevity credits (Nationwide's 75-plus parent uplift and Prudential's tiered longevity credits both come into play here). The carriers page shows the full ranking.

The Bottom Line on Carriers and Treated Hypertension

Treated hypertension on its own, controlled with a single medication, with no cardiovascular event history and no target-organ damage, is one of the more forgiving impairments in modern life insurance underwriting. Most of the 18 carriers in the estimator will consider the top non-tobacco tier for a cleanly treated HTN applicant.

Where carriers diverge is in how they handle the combinations: treated HTN with two medications, treated HTN with elevated cholesterol, treated HTN with family history, treated HTN in older applicants. The 46-point spread on the sample profile comes from those combinations, not from HTN in isolation.

For a shopper or an advisor building an informal inquiry, the practical workflow is: identify which combinations are present, route the case to the carriers whose field guide rules are most favorable for those combinations, and expect a best-fit carrier to outperform a worst-fit carrier by at least 20 to 30 points of top-tier probability on the same applicant.

See how 18 carriers would class your profile or start a longevity report to get a personalized estimate.

Not an advisor? Get your personal longevity report. Health-adjusted life expectancy in seconds.